Biomanufacturing Robotics Firm Multiply Labs Raises $75M Series B, Total Funding Tops $100M
On October 8, 2026, biomanufacturing robotics company Multiply Labs announced the completion of a $75 million Series B funding round led by NantWorks, with participation from AstraZeneca, Teradyne, Lingotto, and existing investors Casdin Capital, Lux Capital, and Founders Fund. The company's total funding has now surpassed $100 million.
Founded in 2016 in San Francisco, Multiply Labs positions itself as a Physical AI infrastructure provider for biomanufacturing, offering flexible automated robotic systems focused on cell and gene therapy production. The new capital will be used to expand the team, accelerate the rollout of automated production lines, and advance the platform from clinical projects to commercial-scale manufacturing.
The company's Physical AI-driven modular robot clusters can replicate the fine operations of experienced researchers, independently performing complex procedures such as sample transfer, reagent handling, and timed incubation. Public benchmark data show that compared with fully manual processes, the system can reduce per-dose production costs by 74% and increase cleanroom throughput per unit area by up to 100 times, while maintaining complete operational data records and meeting FDA 21 CFR Part 11 compliance requirements.
Multiply Labs has established collaborations with AstraZeneca, Legend Biotech, and Kyverna Therapeutics, including a CAR-T therapy automation pilot with Kyverna. It has also partnered with Thermo Fisher Scientific to integrate robotic automation with existing cell processing equipment and completed a proof-of-concept with Stanford Medicine's Laboratory for Cell and Gene Medicine. On the technology side, the company works with NVIDIA, using the Isaac simulation framework and Omniverse digital twin platform to train robotic workflows. To support global delivery, Multiply Labs has set up an overseas subsidiary in Turin, Italy, responsible for robotic cluster supply chain development and scaled production.
